ReviewEye (London, England)2020
New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
Review in Eye (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.The Cochrane database of systematic reviews · 2022Pooled it
- Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 µg and Selective Laser Trabeculectomy in Patients with Open-Angle Glaucoma or Ocular Hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2023Trial
- Aqueous column changes in the episcleral veins after the instillation of ripasudil versus latanoprost: a randomized, double-blind, crossover clinical trial.Scientific reports · 2022Trial
- Promising Glaucoma Medication: A Comprehensive Translational Evaluation.Pharmaceutics · 2026Article
- Global research status in the treatment of glaucoma: a systematic bibliometric analysis.International journal of ophthalmology · 2026Article
- A Comprehensive Review of the Role of Rho-Kinase Inhibitors in Corneal Diseases.Life (Basel, Switzerland) · 2025Review
- Impact of Preoperative Conjunctival Vascular Area on Surgical Outcomes in Trabeculectomy with Mitomycin C for Glaucoma: A Comprehensive Analysis.Vision (Basel, Switzerland) · 2025Article
- Methods for Mitochondrial DNA Damage and Depletion in Immortalized Trabecular Meshwork Cells.International journal of molecular sciences · 2025Article
- Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.Medical gas research · 2025Review
- Lipids and lipid regulators in intraocular pressure homeostasis.Current opinion in pharmacology · 2025Review
- Impact of Oral Citicoline, Antioxidant Vitamins, and Blackcurrant Supplementation on Primary Open-Angle Glaucoma: An OCT and OCTA Study.Biomedicines · 2025Article
- Imaging of aqueous outflow in health and glaucoma. Justifying the re-direction of aqueous.Eye (London, England) · 2025Review
- Combination Therapy with Atropine 0.05% and Myopi-XTurkish journal of ophthalmology · 2025Article
- Rho/ROCK Pathway as a Therapeutic Target in Multiple Diseases.International journal of drug discovery and pharmacology · 2025Article
- Inhibition of pterygium cell fibrosis by the Rho kinase inhibitor.Scientific reports · 2024Article
- Advancing Glaucoma Treatment During Pregnancy and Breastfeeding: Contemporary Management Strategies and Prospective Therapeutic Developments.Biomedicines · 2024Review
- Interplay Between Ocular Ischemia and Glaucoma: An Update.International journal of molecular sciences · 2024Review
- Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review.Bioengineering (Basel, Switzerland) · 2024Review
- Dexamethasone Impairs ATP Production and Mitochondrial Performance in Human Trabecular Meshwork Cells.Current issues in molecular biology · 2024Article
- Crystalline keratopathy following long-term netarsudil therapy.American journal of ophthalmology case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reduction of intraocular pressure is the only proven method to treat glaucoma. Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy. Studies on aqueous humour dynamics have contributed to our understanding of aqueous outflow mechanisms that have led to the discovery of new drugs. Three new drugs (latanoprostene bunod 0.24%, netarsudil 0.02%, and fixed combination netarsudil 0.02% -latanoprost 0.005%) have been introduced recently in the market with novel mechanisms of action. Latanoprostene bunod 0.024% is a nitric oxide-donating prostaglandin F2α analogue which increases the aqueous outflow both by uveoscleral and trabecular pathways. Netarsudil 0.02% is a potent Rho kinase/norepinephrine transporter inhibitor acting by increasing the trabecular outflow, decreasing the aqueous production, and possibly decreasing the episcleral venous pressure. This review highlights the role of these drugs in the management of glaucoma, with an overview of the major clinical trials on their efficacy, safety, and tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.